OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron Era
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
Benjamin Chen, Nina M. Haste, Nancy Binkin, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 9
Showing 9 citing articles:
Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 31
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 31
A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)
Kristin Widyasari, Jin Nam Kim
Antibodies (2023) Vol. 12, Iss. 1, pp. 5-5
Open Access | Times Cited: 24
Kristin Widyasari, Jin Nam Kim
Antibodies (2023) Vol. 12, Iss. 1, pp. 5-5
Open Access | Times Cited: 24
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis
Mabel Nyit Yi Liew, Kok Pim Kua, Shaun Wen Huey Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Mabel Nyit Yi Liew, Kok Pim Kua, Shaun Wen Huey Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
Irma Convertino, Sara Ferraro, Emiliano Cappello, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 231-245
Closed Access | Times Cited: 9
Irma Convertino, Sara Ferraro, Emiliano Cappello, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 231-245
Closed Access | Times Cited: 9
COVID-19 prophylaxis: half-full or half-empty glass?
Lydia Scarfò, Antonio Cuneo
Blood (2023) Vol. 141, Iss. 2, pp. 130-132
Open Access | Times Cited: 3
Lydia Scarfò, Antonio Cuneo
Blood (2023) Vol. 141, Iss. 2, pp. 130-132
Open Access | Times Cited: 3
Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study
Ji‐Man Kang, Juhan Lee, Kyu Ha Huh, et al.
Journal of Clinical Virology (2022) Vol. 159, pp. 105374-105374
Open Access | Times Cited: 5
Ji‐Man Kang, Juhan Lee, Kyu Ha Huh, et al.
Journal of Clinical Virology (2022) Vol. 159, pp. 105374-105374
Open Access | Times Cited: 5
Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan
Toshibumi Taniguchi, Tomoyuki Homma, Yoichi Tamai, et al.
Journal of Infection and Chemotherapy (2024) Vol. 31, Iss. 1, pp. 102467-102467
Closed Access
Toshibumi Taniguchi, Tomoyuki Homma, Yoichi Tamai, et al.
Journal of Infection and Chemotherapy (2024) Vol. 31, Iss. 1, pp. 102467-102467
Closed Access
Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients
Marc Marti-Pastor, Ricardo Bou, Lucia Ciancotti-Oliver, et al.
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 6, pp. 275-280
Closed Access
Marc Marti-Pastor, Ricardo Bou, Lucia Ciancotti-Oliver, et al.
Medicina Clínica (English Edition) (2024) Vol. 163, Iss. 6, pp. 275-280
Closed Access
